Company intelligence
Quanterix
Powering Biomarkers from Discovery to Diagnostics
About Quanterix
Quanterix is a global leader in precision biomarker science, making biology measurable to deliver earlier insights and support breakthroughs in disease research, diagnostics, and drug development. Its Simoa® technology delivers industry-leading sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. Through the acquisition of Akoya Biosciences, Quanterix Spatial solutions deliver high-plex, quantitative protein analysis in tissue at single-cell resolution. Combined with Accelerator Laboratory services, Quanterix gives researchers the tools and expertise to translate discovery into precision diagnostics. Learn more at www.quanterix.com.
Verified activity
Signals from Quanterix
10 published signals
Research & Knowledge
Quanterix announced the Simoa® NPTX2 Advantage PLUS Assay enables quantitative measurement of NPTX2 in human samples to support neurodegeneration research.
Reported by Quanterix
Presence & Recognition
Quanterix hosted a webinar exploring how researchers can build and optimize high-plex biomarker panels to support emerging hypotheses, incorporate new biomarkers, and generate deeper biological insights.
Reported by Quanterix
Presence & Recognition
Quanterix is hosting an upcoming webinar on September 15th featuring Jorge Marques Signes, VP, Laboratory Services, to discuss operational precision in biomarkers for trial enrichment and clinical solutions.
Reported by Quanterix
Products & Services
Quanterix introduced the Simoa APOE Proteotyping Advantage PLUS Kit, which brings APOE4 carrier determination into the same plasma biomarker workflow with no separate genotyping step and no additional sample type.
Reported by Quanterix
Research & Knowledge
Quanterix brand Lucent Diagnostics released LucentAD Complete, a multi-analyte biomarker test from Lucent Diagnostics that detects p-Tau 217, Amyloid Beta (AB42/40 Ratio), Neurofilament Light (NfL), and Glial Fibrillary Acidic Protein (GFAP) in the blood to improve amyloid status classification and reduce the diagnostic gray zone by two-thirds.
Reported by Terri Waller
Presence & Recognition
Quanterix Spatial, formerly Akoya Biosciences, Inc., is attending the 3rd Annual Conference of the European Society for Spatial Biology in Barcelona from September 28 to October 1.
Reported by Alexandra Lo
Presence & Recognition
Quanterix is attending Pri-Med Midwest 2026 in Rosemont, Illinois, at Booth 713 to connect with Lucent Diagnostics and showcase Simoa® technology.
Reported by Alexandra Lo
Research & Knowledge
Quanterix published an application note exploring why measuring IL-17F alongside IL-17A may provide a more complete picture of the IL-17 pathway activity and therapeutic response.
Reported by Alexandra Lo
Presence & Recognition
Quanterix is hosting a virtual webinar on September 15 at 11 a.m. ET to explore biomarker operations and clinical trial enrichment.
Reported by Alexandra Lo
Research & Knowledge
Quanterix published an application note exploring why measuring IL-17F alongside IL-17A may provide a more complete picture of the IL-17 pathway activity and therapeutic response in psoriasis.
Reported by Quanterix